Phaseline

Companies › STCube

STCube: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nelmastobart
BTN1A1 agonist
BTN1A1Phase 2Non Small Cell Lung Cancer; Metastatic Colorectal Cancer (CRC)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06873763NelmastobartPhase 1Metastatic Colorectal Cancer (CRC)OncologyMar 2027
NCT07306624NelmastobartPhase 2Non Small Cell Lung CancerOncologyAug 2027

Targets

BTN1A1 (1)

Companies with the same targets

–

Companies built like this

CrystalGenomics Partner Therapeutics Ambrx Convergent Therapeutics I-Mab Biopharma US

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.